Under the Public Readiness and Emergency Preparedness Act, the HHS secretary declared Emergent BioSolutions' anthrax products, Anthrax Immune Globulin and Biothrax vaccine, covered countermeasures to a public health crisis. The act, which is in effect until Dec. 31, 2015, will protect Emergent and other manufacturers from lawsuits to encourage them to develop treatments for anthrax and other serious health risks.

Related Summaries